Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have earned an average rating of “Moderate Buy” from the nineteen ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, fifteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $241.5294.

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $245.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, May 7th. TD Cowen upped their target price on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their target price for the company from $188.00 to $307.00 in a report on Tuesday. Sanford C. Bernstein initiated coverage on shares of Jazz Pharmaceuticals in a report on Thursday. They issued a “market perform” rating and a $229.00 price target on the stock. Finally, Royal Bank Of Canada increased their price target on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Norbert G. Riedel sold 3,415 shares of the stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $192.00, for a total value of $655,680.00. Following the transaction, the director directly owned 7,024 shares of the company’s stock, valued at $1,348,608. This represents a 32.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Patricia Carr sold 1,287 shares of the stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $182.94, for a total transaction of $235,443.78. Following the completion of the transaction, the chief accounting officer directly owned 6,512 shares in the company, valued at approximately $1,191,305.28. This represents a 16.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 74,015 shares of company stock worth $14,180,486. 4.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of JAZZ. Hilltop National Bank bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at about $36,000. LRI Investments LLC bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at about $38,000. Danske Bank A S bought a new position in Jazz Pharmaceuticals in the 3rd quarter valued at about $40,000. Geneos Wealth Management Inc. raised its holdings in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its holdings in Jazz Pharmaceuticals by 1,383.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 332 shares during the period. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Stock Up 0.2%

Shares of JAZZ stock opened at $239.83 on Monday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The firm’s 50-day moving average is $202.44 and its 200-day moving average is $179.99. The stock has a market cap of $15.05 billion, a price-to-earnings ratio of -11,985.51, a PEG ratio of 0.43 and a beta of 0.27. Jazz Pharmaceuticals has a 52-week low of $105.00 and a 52-week high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The company had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Sell-side analysts predict that Jazz Pharmaceuticals will post 20.75 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.